Literature DB >> 29177633

Osteoporosis is associated with increased risk for benign paroxysmal positional vertigo: a nationwide population-based study.

Kai-Chieh Chan1,2,3, Yao-Te Tsai2,3,4, Yao-Hsu Yang5,6,7, Pau-Chung Chen8,9, Po-Hung Chang10,11,12.   

Abstract

Recent evidence has indicated that osteoporosis is a risk factor for benign paroxysmal positional vertigo (BPPV). This large population-based study demonstrated that patients with osteoporosis had a 1.82-fold higher risk of developing BPPV than those without osteoporosis through the use of the Taiwan National Health Insurance Research Database.
PURPOSE: Benign paroxysmal positional vertigo (BPPV) is one of the most frequent causes of vertigo. Osteoporosis reflects a homeostatic imbalance in the rate of bone turnover, with the rate of bone resorption exceeding that of bone formation. Recent evidence has indicated that osteoporosis is a risk factor for BPPV. We aimed to validate the risk of BPPV in osteoporotic patients through a nationwide, population-based, cohort study.
METHODS: Patients treated for osteoporosis were identified from entries made in the Taiwan National Health Insurance Research Database (NHIRD) between 2000 and 2013. Each osteoporosis patient was age- and sex-matched with four randomly selected subjects without osteoporosis. We compared the incidence rates of BPPV in the two cohorts (with and without osteoporosis) and identified risk factors.
RESULTS: We identified 6649 osteoporosis patients and 26,596 match controls. According to the incidence of BPPV among the two groups, patients with osteoporosis were found to have a 1.82-fold higher risk of developing BPPV than those without osteoporosis. The incidence rate ratio (IRR) between osteoporotic patients and the control cohort was 2.0 (p < 0.001).
CONCLUSIONS: This large population-based study demonstrated that patients with osteoporosis were associated with an increased risk for BPPV. The results of this study provide some insight into the management of BPPV.

Entities:  

Keywords:  BPPV; Osteoporosis; Vertigo

Mesh:

Year:  2017        PMID: 29177633     DOI: 10.1007/s11657-017-0403-7

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  7 in total

1.  The prevalence of benign paroxysmal positional vertigo in patients with osteoporosis.

Authors:  Tjasse D Bruintjes; Hester J van der Zaag-Loonen; Frank Eggelmeijer; Roeland B van Leeuwen
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-12       Impact factor: 2.503

2.  Association between bone mineral density and benign paroxysmal positional vertigo: a meta-analysis.

Authors:  Ling-Ling He; Xin-Yi Li; Miao-Miao Hou; Xiao-Qiong Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-27       Impact factor: 2.503

Review 3.  Benign paroxysmal positional vertigo in the elderly: current insights.

Authors:  D G Balatsouras; G Koukoutsis; A Fassolis; A Moukos; A Apris
Journal:  Clin Interv Aging       Date:  2018-11-05       Impact factor: 4.458

4.  Increased risk of benign paroxysmal positional vertigo in osteoporosis: a nationwide population-based cohort study.

Authors:  Hayoung Byun; Jae Ho Chung; Seung Hwan Lee; Chul Won Park; Eun Mi Kim; Inah Kim
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

5.  Benign Paroxysmal Positional Vertigo and the Increased Risk of Ischemic Stroke: A Nested Case-Control Study Using a National Cohort Sample.

Authors:  Hyo Geun Choi; So Young Kim
Journal:  Biomed Res Int       Date:  2021-02-20       Impact factor: 3.411

6.  Dizziness and benign paroxysmal positional vertigo among retirement home residents: a cross-sectional descriptive and interventional study.

Authors:  Rainer Müller; Peter Zangger; Dominik Straumann; Stefan Y Bögli
Journal:  BMC Geriatr       Date:  2022-02-12       Impact factor: 3.921

7.  Clinical Characteristics and Risk Factors for the Recurrence of Benign Paroxysmal Positional Vertigo.

Authors:  Cui Ting Zhu; Xing Qquan Zhao; Yi Ju; Yan Wang; Mei Mei Chen; Yu Cui
Journal:  Front Neurol       Date:  2019-11-13       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.